Immunome, Inc. (NASDAQ:IMNM - Get Free Report) was down 4.5% during mid-day trading on Thursday . The company traded as low as $20.55 and last traded at $20.63. Approximately 287,653 shares changed hands during mid-day trading, a decline of 59% from the average daily volume of 704,096 shares. The stock had previously closed at $21.60.
Analyst Ratings Changes
A number of analysts have issued reports on IMNM shares. SVB Leerink initiated coverage on Immunome in a research report on Monday, January 29th. They issued an "outperform" rating and a $30.00 target price on the stock. Leerink Partnrs restated an "outperform" rating on shares of Immunome in a research note on Monday, January 29th. Finally, Wedbush boosted their price target on shares of Immunome from $27.00 to $33.00 and gave the stock an "outperform" rating in a research note on Monday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $31.50.
Check Out Our Latest Report on IMNM
Immunome Price Performance
The business's 50 day moving average is $23.00 and its 200 day moving average is $13.98. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -3.76 and a beta of 1.66.
Hedge Funds Weigh In On Immunome
A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Immunome by 339.0% during the fourth quarter. Vanguard Group Inc. now owns 1,740,026 shares of the company's stock worth $18,618,000 after purchasing an additional 1,343,697 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Immunome by 505.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,051,222 shares of the company's stock valued at $11,249,000 after acquiring an additional 877,592 shares during the last quarter. Barclays PLC purchased a new stake in Immunome in the fourth quarter valued at $882,000. Royal Bank of Canada lifted its position in Immunome by 3.2% in the fourth quarter. Royal Bank of Canada now owns 29,484 shares of the company's stock valued at $315,000 after acquiring an additional 928 shares during the last quarter. Finally, Point72 Asset Management L.P. lifted its position in Immunome by 25.0% in the fourth quarter. Point72 Asset Management L.P. now owns 682,619 shares of the company's stock valued at $7,304,000 after acquiring an additional 136,700 shares during the last quarter. Institutional investors and hedge funds own 44.58% of the company's stock.
About Immunome
(
Get Free Report)
Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.
Featured Stories
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
